Biovail Corporation announced
today that Wellbutrin XL, the first once-daily extended-release formulation of
bupropion hydrochloride approved for the Canadian market for the treatment of
depression in adults, has been officially launched and is commercially available.
Wellbutrin XL, is being marketed and distributed by Biovail Pharmaceuticals Canada
(BPC), the Canadian sales and marketing division of Biovail Corporation. Wellbutrin
XL, which received a Notice of Compliance from the Therapeutic Products Directorate
(Canada) in January 2006, is available in 150mg and 300mg dosage strengths.